Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a California-based biotechnology company focused on rare and ultra-rare genetic diseases, has secured standard full approval from the U.S. Food and Drug Administration for Fayuvi, a one-time gene therapy for pediatric patients with mucopolysaccharidosis type IIIA, also known as Sanfilippo syndrome Type A. The approval creates the first FDA-authorized treatment for the progressive and ultimately fatal neurological disease, replacing a treatment landscape that had previously been limited to managing symptoms rather than addressing the underlying biological cause.
The regulatory decision has also delivered a significant change in investor sentiment around Ultragenyx after a difficult September. Shares closed 12.58% higher at $14.50 on September 17 following the approval and held those gains on September 18, ending at $14.51 on trading volume of more than 13 million shares. That rebound is meaningful, but it comes against a much deeper decline earlier in the month, leaving the stock roughly 45% below its September 2 closing price of $26.53.
The commercial stakes are equally notable. Reuters reported that Ultragenyx has set the U.S. list price for Fayuvi at $3.95 million for the one-time treatment, placing the therapy among the world’s most expensive medicines. The company expects commercial product to become available for shipment to qualified U.S. treatment centers within approximately 30 to 60 days, meaning the next test will move rapidly from regulatory approval to patient identification, reimbursement and real-world execution.
Why is the FDA approval of Fayuvi important for Sanfilippo syndrome Type A?
Sanfilippo syndrome Type A is an ultra-rare lysosomal storage disease caused by deficiency of the SGSH enzyme, also known as sulfamidase. Without sufficient enzyme activity, heparan sulfate accumulates within cells and progressively damages the brain and nervous system, leading initially to developmental problems and eventually to deterioration in cognitive, language and motor abilities. Ultragenyx estimates that approximately 3,000 to 5,000 patients live with the condition across commercially accessible markets and puts median life expectancy at around 15 years.
Fayuvi, formally known as rebisufligene etisparvovec-hopf and previously developed as UX111, is designed to intervene much earlier in that biological process. The therapy uses an adeno-associated virus serotype 9 vector to deliver a functioning copy of the SGSH gene, enabling cells to produce the missing sulfamidase enzyme and improve the breakdown of accumulated heparan sulfate. Unlike chronic medicines that need repeated dosing, Fayuvi is administered as a single intravenous infusion.
The FDA described the approval as the first treatment capable of addressing the course of Sanfilippo syndrome Type A rather than simply controlling individual symptoms. That distinction is particularly significant because neurological damage from the disease is progressive and irreversible, making diagnosis and treatment while children retain neurodevelopmental function especially important. The approved indication therefore covers pediatric patients who still have preserved neurodevelopmental function.
What clinical evidence convinced the FDA to grant full approval?
The regulatory decision was supported principally by the Transpher A clinical program and longer-term follow-up comparing treated children with patients drawn from an external natural-history cohort. Ultragenyx reported that clinical follow-up now extends to nearly eight years in some patients, giving regulators a longer view of durability than is available for many newly introduced gene therapies.
Clinical efficacy was assessed through changes in Bayley-III Cognitive raw scores between 24 and 60 months of age. Seventeen treated patients in the modified intention-to-treat population were compared with 27 untreated children from a comparable natural-history cohort, with the Fayuvi group showing a 23.5-point higher cognitive score during the assessment period. Ultragenyx reported a p-value below 0.0001, while the FDA said treated patients maintained or improved cognitive function relative to the expected plateau and decline seen among untreated children.
Biochemical evidence supported the clinical findings. Ultragenyx said cerebrospinal-fluid heparan sulfate concentrations declined following treatment across age groups, providing evidence that the therapy was replacing the missing enzyme and affecting the biochemical mechanism responsible for the disease. Importantly, the FDA granted standard full approval rather than relying on a provisional commercial pathway, giving Fayuvi a stronger regulatory footing as Ultragenyx begins the U.S. launch.
The approval nevertheless does not remove the monitoring requirements associated with systemic AAV gene therapy. The FDA identified liver-enzyme elevations, vomiting, fever, reduced appetite and reductions in white blood cells and platelets among commonly observed adverse reactions, while the prescribing information includes monitoring for hepatotoxicity, thrombocytopenia and potential thrombotic microangiopathy. Patients also receive corticosteroids beginning before infusion and continuing for at least eight weeks afterward.
Why does Fayuvi’s $3.95 million price matter for the commercial launch?
The $3.95 million U.S. list price immediately makes reimbursement one of the most important variables surrounding the launch. Gene therapies are structurally different from conventional pharmaceuticals because the entire therapeutic value and much of the cost are concentrated into a single administration, forcing insurers and healthcare systems to evaluate large upfront payments against the potential cost of years of disease management and supportive care. Reuters reported that Ultragenyx has pointed to lifetime care expenses that may reach approximately $8 million for affected children as part of the economic context around the treatment.
That does not mean every eligible patient will automatically receive treatment soon after launch. Ultra-rare gene therapies require diagnostic identification, referral to specialized centers, insurance authorization and significant clinical preparation before administration, meaning revenue can develop unevenly even after a successful FDA approval. Ultragenyx plans to distribute Fayuvi through qualified treatment centers with specialist gene-therapy capabilities and is using its UltraCare program to help families navigate insurance coverage and treatment logistics.
Manufacturing could also become an important differentiator. Ultragenyx said Fayuvi is manufactured entirely in the United States through its gene-therapy manufacturing facility in Bedford, Massachusetts, and Andelyn Biosciences in Columbus, Ohio. Andelyn separately confirmed that it is manufacturing commercial supply following the approval, giving Ultragenyx an established domestic production network as demand begins to move from clinical trials toward commercial treatment.
Reuters cited analyst estimates placing potential peak global Fayuvi sales in the range of roughly $200 million to $250 million. That would not make Fayuvi the company’s largest commercial franchise on its own, but the economics can still be strategically meaningful because Ultragenyx is simultaneously trying to expand its approved rare-disease portfolio, reduce operating losses and move toward profitability.
Why did Ultragenyx stock rebound after losing 44% earlier in September?
The timing of the approval helps explain the intensity of the market reaction. Ultragenyx entered September with substantially higher expectations around apazunersen, also known as GTX-102, an experimental antisense therapy for Angelman syndrome. On September 2, the company disclosed that its Phase 3 Aspire study had failed both its primary endpoint involving Bayley-4 cognitive raw scores and its key secondary endpoint based on the Multidomain Responder Index.
Management said the treated and control groups showed no efficacy differences capable of supporting a benefit across the principal cognitive measure or individual components of the secondary endpoint. Ultragenyx consequently said it would evaluate the future of the apazunersen program and reassess its planned operations, including significant expense reductions. Investors reacted aggressively, with RARE shares falling approximately 44% during the September 3 session.
The Fayuvi approval therefore does more than add another product. It provides concrete regulatory validation for Ultragenyx’s gene-therapy capabilities at a moment when confidence in another major pipeline program had deteriorated sharply. Fayuvi is also the company’s second approved gene therapy and sixth FDA-approved treatment overall, following the August approval of Genglycos for glycogen storage disease Type Ia.
The share-price picture nevertheless shows why sentiment remains mixed rather than uniformly optimistic. The September 17 rally recovered only part of the value lost after the Aspire failure, and the $14.51 September 18 closing price remained roughly 45% below where Ultragenyx traded immediately before that setback. The market is therefore recognizing a genuine commercial win without erasing the financial consequences of losing a potentially important late-stage pipeline asset.
Can two gene therapy approvals change Ultragenyx’s financial trajectory?
Ultragenyx entered this period with a commercial business already generating substantial revenue. Second-quarter 2026 revenue reached a company-record $214 million, up from $167 million a year earlier, while management maintained full-year revenue guidance of $730 million to $760 million. Importantly, that guidance excluded revenue from potential new product launches, meaning Genglycos and Fayuvi can provide incremental commercial contribution if their launches progress successfully.
The company has not yet reached profitability. Ultragenyx reported a second-quarter net loss of $92 million and held $436 million in cash, cash equivalents and marketable securities at June 30, while consuming $97 million of cash in operations during the quarter. Management had previously said it remained on a path toward profitability in 2027, although the Aspire failure subsequently prompted plans for further expense reductions.
Fayuvi therefore arrives at a consequential point in the company’s evolution. Commercial success would broaden Ultragenyx beyond its established products, demonstrate that its internally supported gene-therapy infrastructure can generate revenue from multiple diseases and potentially improve the economics of maintaining manufacturing capacity for future programs. The Priority Review Voucher awarded with the approval also provides an additional strategic asset that the company could use for another program or potentially monetize, depending on future corporate priorities.
The more immediate question is how rapidly Ultragenyx can convert regulatory success into treated patients. With commercial shipments expected within 30 to 60 days, investor attention is likely to shift toward treatment-center activation, payer coverage, patient identification and initial launch indicators. Those milestones will determine whether the Fayuvi approval becomes primarily an important scientific achievement or develops into a material new contributor to Ultragenyx’s commercial recovery.
